A federal court has ordered the Drug Enforcement Administration to respond to a lawsuit charging the agency with failing to move forward with a 2016 policy to expand the total number of federally licensed marijuana cultivators.
Federal officials have approved plans for the University of Mississippi to grow 2,000 kilograms (4,409 pounds) of cannabis to provide to investigators for clinical trial research.
Members of the US Senate Committee on Agriculture, Nutrition, and Forestry will hear expert testimony next week regarding the production of industrial hemp and hemp-derived products.
In its written testimony, NORML Deputy Director Paul Armentano encourages the agency to act expeditiously to clarify confusion among both consumers and regulators with regard to the legality of specific CBD products. It further recommends that the FDA provide regulatory guidelines governing product manufacturing, standardization, and quality.
NORML has submitted written comments to the US Food and Drug Administration ahead of the agency’s scheduled hearing on the regulation CBD-infused products. The agency will be taking in person public testimony on Friday, May 31, with regard to the “manufacturing, product quality, marketing, labeling, and sale” of CBD-infused retail products.
Marijuana grown by the University of Mississippi for clinical research purposes is genetically divergent from strains of cannabis commercially available in retail markets, according to an analysis prepared by researchers at the University of Northern Colorado.
Regulators at the US Food and Drug Administration today granted market approval for Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.
While many are already celebrating the holidays with family and loved ones, we didn’t want to miss the chance to spotlight some important marijuana law reforms that have taken place this past week. We have exciting news internationally, federally, and in several states! Keep reading below to find out more!
Members of the US Senate at a hearing yesterday expressed skepticism in regard to federal policies limiting the ability of investigators to engage in clinical studies of marijuana’s health benefits. Senators heard from representatives from the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), National Institute on Drug Abuse (NIDA), University of Mississippi Medical Center, Arrowhead Regional Medical Center and Project SAM on a variety of issues The hearing’s most noteworthy moment came when Nora Volkow, director of NIDA, acknowledged that the monopoly on marijuana cultivation for research purposes […]
[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To have NORML’s news alerts and legislative advisories delivered straight to your in-box, sign up here.] The use of cannabis and cannabinoids appears to mitigate symptoms associated with post-traumatic stress disorder (PTSD), according to a new review of clinical and preclinical evidence published online in the scientific journal Drug Testing and Analysis. An international team of investigators from Germany, the United States, and the United Kingdom reported that the use of cannabis to “dramatically reduced” PTSD […]